GlassScriptPhysician profile
Dordaneh Maleki
NPI 1356378574
$2,900.61
in general payments reported to CMS, 2019-2025
22 companies · $434 in 2025
The $434 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $456 · 2022: $246 · 2023: $652 · 2024: $785 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,855 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,855.05 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $1,021.29 | 2019-2025 | Sucraid, Sucraid |
| Abbvie INC. | $641.38 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $292.68 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $172.08 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $132.20 | 2019-2024 | Dificid |
| Gilead Sciences, INC. | $115.33 | 2023-2025 | |
| Evoke Pharma, INC. | $94.42 | 2023-2025 | Gimoti |
| Madrigal Pharmaceuticals | $52.42 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.06 | 2023-2025 | Xifaxan, Relistor |
| Genzyme Corporation | $41.19 | 2023-2024 | |
| Braintree Laboratories, INC. | $40.92 | 2019-2023 | Sutab |
| Redhill Biopharma INC. | $39.33 | 2022-2023 | Aemcolo, Talicia, Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $29.32 | 2019 | |
| Intercept Pharmaceuticals, INC. | $27.55 | 2019 | |
| Boston Scientific Corporation | $27.12 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $26.70 | 2019-2020 | |
| Ardelyx, INC. | $20.75 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $18.96 | 2024 | Dupixent |
| Aimmune Therapeutics, INC. | $16.60 | 2024 | |
| Nestle Healthcare Nutrition INC. | $16.11 | 2023 | |
| Pfizer INC. | $13.19 | 2019 | |
| Alfasigma USA, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dordaneh Maleki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.